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Recent high-throughput transcript discoveries have yielded a growing recognition of long
intergenic non-coding RNAs (lincRNAs), a class of arbitrarily defined transcripts (>200nt)
that are primarily produced from the intergenic space. lincRNAs have been increasingly
acknowledged for their expressional dynamics and likely functional associations with
cancers. However, differential gene dosage of lincRNA genes between cancer genomes
is less studied. By using the high-density Human Omni5-Quad BeadChips (Illumina), we
investigated genomic copy number aberrations in a set of seven tumor-normal paired
primary human mammary epithelial cells (HMECs) established from patients with invasive
ductal carcinoma. This Beadchip platform includes a total of 2,435,915 SNP loci dispersed
at an average interval of ∼700 nt throughout the intergenic region of the human genome.
We mapped annotated or putative lincRNA genes to a subset of 332,539 SNP loci, which
were included in our analysis for lincRNA-associated copy number variations (CNV). We
have identified 122 lincRNAs, which were affected by somatic CNV with overlapped
aberrations ranging from 0.14% to 100% in length. lincRNA-associated aberrations were
detected predominantly with copy number losses and preferential clustering to the ends
of chromosomes. Interestingly, lincRNA genes appear to be less susceptible to CNV in
comparison to both protein-coding and intergenic regions (CNV affected segments in
percentage: 1.8%, 37.5%, and 60.6%, respectively). In summary, our study established
a novel approach utilizing high-resolution SNP array to identify lincRNA candidates, which
could functionally link to tumorigenesis, and provide new strategies for the diagnosis and
treatment of breast cancer.
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INTRODUCTION
Long intergenic non-coding RNAs (lincRNAs) are intergenic
region-derived, large transcripts (>200 nucleotides) that do
not give rise to proteins. lincRNAs, together with other long
non-coding RNAs (lncRNAs), such as antisense, interleaved,
and protein-coding-gene-overlapped lncRNAs, are actively tran-
scribed from the genome, and consist of a substantial fraction
of the human transcriptome (Carninci et al., 2005; Mattick and
Makunin, 2006). Approximately 20–40% of the total genome is
estimated to produce lncRNAs vs. less than 2% represented by
protein-coding mRNAs (Nagano and Fraser, 2011), which stim-
ulated intensive interest in the exploration of the gene structures,
expressional signatures and functionality of lncRNAs. Long inter-
genic non-coding RNAs (lincRNA) have recently come to our
attention as a result of an increased intergenic coverage of whole
transcriptome and sequencing analysis.
By means of various high throughput approaches, the
population of identified human lincRNA transcripts is
rapidly expanding—from a class of ∼3300 identified using
chromatin-state mapping (Khalil et al., 2009) to a substantial
catalog of over 8000 assembled from four billion RNA-seq
reads (Cabili et al., 2011). This number, though reaching as
much as one-fifth of mRNAs, represents a conservatively lower
estimate of lincRNAs, most of which remain unannotated.
Moreover, the nucleotide sequences of lincRNAs appear to
be evolutionarily conserved among mammals, especially their
promoters that exhibit a strong conservation resembling known
protein-coding genes, suggesting they are functional despite
the lack of protein-coding capacity (Guttman et al., 2009,
2010). Indeed, accumulating evidence has demonstrated various
functionalities of annotated lincRNAs or even specific individual
lincRNAs in mammals and humans (Gupta et al., 2010; Huarte
et al., 2010; Keniry et al., 2012; Yoon et al., 2012). In addition to
their tissue- and cell-specific expression signatures (Cabili et al.,
2011), epigenetic regulation of gene expression, and involvement
in developmental processes (Loewer et al., 2010; Guttman et al.,
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2011), dysregulation in cancers and their functional mechanisms
involved in tumor development, including breast tumorigenesis,
have begun to be investigated. Notably, a recent finding showed
that numerous lincRNAs in the HOX loci demonstrated differ-
ential expression in primary breast carcinomas and metastases,
particularly with HOTARI expression being up-regulated by
thousands of fold, leading to the proposal that it is an indepen-
dent prognostic biomarker for breast cancer metastasis (Gupta
et al., 2010).
Breast cancer is among the most lethal malignant diseases in
women (Howlader et al., 2012). Analyses of this disease using
existing large-scale whole-genome technologies have revealed
complex genomic aberrations which are believed to be the driving
force of its initiation or progression (Stephens et al., 2009; Banerji
et al., 2012; Ha et al., 2012). In addition to point genomic changes,
large-scale structural alterations, including genomic copy num-
ber variation (CNV) and loss-of-heterozygosity (LOH) in breast
tumors, though less well-understood, appear to be major contri-
butors to this tumorigenesis.
CNV typically refers to genomic changes in terms of vari-
able numbers of copies of a >1 kb DNA segment in comparison
to a reference genome (Feuk et al., 2006). CNV regions of the
genome are often mapped by many dosage-sensitive genes since
copy gains or losses of these genes primarily determine their
expression (Feuk et al., 2006; Zhou et al., 2011). Studies on corre-
lations between CNVs of protein coding genes and corresponding
expression levels, have indicated that approximately 60% of cellu-
lar expression variation and expression-associated phenotypes are
accounted for by CNVs (with the exception of brain) (Henrichsen
et al., 2009). Recent SNP array data from a collection of over 2000
breast cancer samples indicated that inherited and somatically
acquired tumor CNVs had a strong influence on the expres-
sion of approximately 40% of genes (Curtis et al., 2012). While
the majority of these array analyses have largely emphasized the
protein-coding genes, none of the reports have included inves-
tigation of the intergenic non-coding genes harboring CNVs.
This is likely due to the lack of high-density array coverage and
inadequate annotations in intergenic regions.
Since genetic structural variations of breast cancer-associated
lincRNAs have not been reported, we sought out to examine the
CNV of lincRNA genes between tumors and matched adjacent
normal host counterparts using HumanOmni5 Quad Beadchips.
This platform provides a high coverage of the intergenic por-
tion of the genome for high-resolution aberration detection. By
using this technology, we hope to identify lincRNA associated
genomic variations that may influence the progression of this
disease.
MATERIALS AND METHODS
PAIRED BIOPSIES AND PRIMARY EPITHELIAL CULTURE
The breast tumors and adjacent non-tumor tissues were
obtained from breast cancer patients who underwent lumpec-
tomy/mastectomy from 2008 to 2009, with informed consent
as approved by the Institution Review Board (IRB) at the Fox
Chase Cancer Center (FCCC). The pathological histotypes of
tumors included in this study were all invasive ductal carcinoma
(IDC) at stage II or greater (Table 1). Tumor cells and matched
Table 1 | Clinical information for breast cancer patients.
Case Age/ Tumor Tumor IHC marker status Gradeb
ID Sex type sizea, cm
ER PR HER2-Neu
BC-1 49/F IDCc 3.3 − − − III
BC-2 40/F IDC 5.5 − − + III
BC-3 50/F IDC 0.8 − − + III
BC-4 56/F IDC 0.2 − − + II
BC-5 38/F IDC 3.2 + + − II
BC-6 62/F IDC 5.5 + + Ed II
BC-7 33/F IDC 1.8 + + − III
aTumor size is determined at greatest dimension.
bGrading is according to modified Bloom-Richardson grade.
c IDC, Invasive Ductal Carcinoma.
dEquivocal: negative by FISH.
normal epithelial cells were enriched and cultured according to
a commercial Human Mammary Epithelial Cell Culture Protocol
(Stemcell technologies, Vancouver, BC, Canada), and maintained
the same procedure for all the samples. Briefly, breast tissues
were incubated and minced in EpiCult®-B Medium supple-
mented with 5% fetal bovine serum. Tissue fragments were
then suspended in an addition of 1×Collagenase/Hyaluronidase
solution to the same medium and rotated overnight at 37◦C.
Contaminated fat was removed from the overlying liquefied
layer following a centrifugation at 80× g for 30 s. Epithelial
organoid enriched pellets were resuspended in Trypsin-EDTA
(0.25%) for 1–3min and washed in Hanks’ Balanced Salt
Modified Solution supplemented with 2% FBS. Occasional cell
clumps were briefly dissociated in 2mL of 5mg/mL Dispase
and 200µL of 1mg/mL DNase I. Single epithelial suspensions
were further filtered through a 40µm cell strainer, pelleted and
cultured.
GENOMIC DNA ISOLATION AND SNP ARRAY
Genomic DNAs used in the global CNV analysis here were derived
from paired normal-tumor primary human mammary epithelial
cell lines (passage < 6) as previously described (Godwin et al.,
1994). These primaryHMEC lines represent the native breast nor-
mal and malignant epithelial cell populations, which we believe
provides a unique advantage to studying breast cancer-associated
lincRNA. Themicroarray assay was performed using the Infinium
HD Human Omni-5 Quad Beadchip (Illumina Inc., San Diego,
CA, USA). This SNP array consists of >4.3 million SNPs selected
from the International HapMap Project and the 1000 Genome
Project. A high density coverage of intergenic regions of the
genome with over 2.4 million markers (average mean marker
spacing of ∼700 nt bp) provides an ideal tool to analyze lin-
cRNA genes. For the SNP array, 400 ng (nanograms) of DNA,
quantified by PicoGreen assay, were subjected to whole genome
application and fragmentation, and applied to HumanOmni5
beadarrays. The scanned signal raw intensities for each array were
assessed and analyzed with GenomeStudio Software (Illumina
Inc., San Diego, CA, USA) using default normalization to gen-
erate X and Y intensity values for A and B alleles (generic labels
for two alternative SNP alleles), respectively. An Illumina clus-
ter file for HumanOmni5, generated by using a set of more
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than 200 HapMap samples, was used to computate two types
of measurements for each probe: log R ratios (LRRs, log2
Rsubject/Rexpected) and B allele frequencies [BAFs, B/(A + B)],
which provide information on copy number and genotyping.
CNV ANALYSIS USING NEXUS
Tab-delimited bead summary data containing LRRs and BAFs
were exported using a Nexus plug-in in the GenomeStudio, and
CNV detection was performed using Nexus 6.0 (BioDiscovery,
CA). Samples were loaded into Nexus by using a sample descrip-
tor with matched pair design, where data from the normal sample
are subtracted from that of the tumor sample to produce one
result. Data from two paired replicate arrays were combined for
normal samples and tumors, respectively. Probes mapping to the
Y chromosome and SNPs with incorrect genotyping were filtered
prior to importation to Nexus. Samples are subjected to quality
assessment with a quality score below 0.02 (where the lower value
represents a better quality). A linear correction was used to correct
GC wave, and SNP-FASST2 segmentation algorithm was applied
to generate CNV calls. A customized lincRNA annotation track
was created on the basis of reference lincRNA (described below)
to aid lincRNA specific CNV detection. Since the Nexus default
gene track includes genes for known protein-coding as well as
some of the non-coding genes, a customized protein-coding gene
specific annotation track was also created to analyze CNV for
the protein coding genes, which serves as an internal control for
lincRNAs.
lincRNA LOCI DATABASE
lincRNA reference is retrieved from the online genomic database
Ensembl release 67, built on the Genome Reference Consortium
release GRCh37 using the BioMart data management system.
At Ensembl, lincRNA genes are in silico annotated using cDNA
sequences (1) mapping to chromatin methylation sites outside
protein coding loci, and (2) lacking protein-coding potentials
(Ensembl). Given the dynamics of the number of lincRNAs
in the database, other possibly relevant non-coding transcripts
were also included to create a putative list. This list consisted
of 6459 lincRNA and non-coding genes with starting and end-
ing coordinates. Next, the intergenic SNPs from HumanOmni5
were subsetted and used to query the lincRNA putative list to
remove any transcripts that were not present in intergenic regions
to obtain a full probe list of 332,540 and a final reference list
of 5800 lincRNA genes (Table S1). A protein-coding reference
consisting of 22,088 genes was also obtained from Ensembl for
the generation of a customized track in Nexus. Frequencies of
CNV calls for lincRNA or genic regions from seven matched
tumor-normal pairs were retrieved using the aggregate func-
tion of the Nexus package. Data were then formatted and input
into Circos (http://circos.ca/, Krzywinski et al., 2009) using Perl
(http://www.cpan.org/ports). Whole genome views of CNV fre-
quencies for lincRNA or genic regions were created in PNG
format.
QUANTITATIVE REAL-TIME PCR (qPCR)
Quantitative PCR (qPCR) was performed in the ABI 7900HT
system using Power Syber® Green assays for targeted gene
content and TaqMan assays for copy number references includ-
ing alpha-satellite sequence and albumin both using a 5′ FAM/3′
BHQ labeled probe (Applied Biosystem). Primer and probe
sequences are available upon request. Experiments were carried
out using two levels of gDNA inputs for each sample in 384
microwell plates, and in triplicates for each level. Each reac-
tion consisted of a 10µL system containing 40 ng or 10 ng
gDNA input in 5 ng/µL tRNA carrier (Roche Diagnostics), 5µL
Power Syber Green Master Mix® or TaqMan Master Mix, and
0.4µL primer mixes. Standard curves for references and for
target genes using 64, 16, 4, 1, 0.25, and 0.0625 ng of commer-
cial gDNA from a healthy female (Promega) were performed
in triplicate or quadruplicate with R square values of 0.99 or
above according to a previous method (D’Haene et al., 2010).
For positive controls, we did not use any lincRNAs that har-
bor CNV in our samples as positive or negative controls since
this area has not been well explored yet. Therefore, we used
known CDKN2A CNV on known CNV-affected samples to
test the sensitivity of qPCR. In addition, non-template con-
trols (NTC) were included in triplicates for each plate. Thermal
cycling conditions were 95◦C for 10min followed by 40 cycles
of 95◦C for 15 s and 60◦C for 1min. The unknown sample’s
DNA quantity is calculated from a linear regression model
for a threshold cycle (Ct) relative to DNA starting amount
normalized by references. The ratio of DNA quantity means
between tumor and normal samples was used to determine
somatic copy number changes. Two or more non-call samples
were determined in parallel as negative controls. The 2−Ct
method was also used to compare the results from a different
analysis.
STATISTICAL ANALYSIS
The proportions of lincRNA, genic and intergenic region-
associated CNVs in length were analyzed using the two-tailed
Wilcoxon signed rank test. Data distributions are presented
as box plots. A Type I Error of 0.05 was used to deter-
mine statistical significance. In addition, linear regression
was performed between lincRNA and genic regions for all
samples.
RESULTS
lincRNA CNVs DISCOVERY
A total of 14 primary cell lines from 7 matched breast can-
cers and 7 surrounding healthy normal tissues were investi-
gated by the HumanOmni5 Beadchips. Sample dataset outputs
from GenomeStudio were quality-assessed by using log inten-
sity plots between tumor and paired normal samples prior to
importation into Nexus. CNV calls were initially generated as
discordant logRRs that did not map to the HumanOmni5 ref-
erence derived from HapMap samples. These were subsequently
improved by using the pair matched analysis where each tumor
was adjusted by the corresponding matched normal sample
since substantial noise was produced under the unpaired model.
lincRNA-associated CNV calls were specifically identified as CNV
regions that include or overlap reference lincRNA gene posi-
tions. Overall, 86 lincRNA-associated somatic aberration events,
including copy gains/losses and allelic imbalances ranging in size
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Table 2 | Large-scale lincRNA involved genomic copy number changes and allelic imbalances detected by Illumina HumanOmni5 array.
Case ID CN gains CN losses Allelic imbalances
Cytoband lincRNAs (n) Cytoband lincRNAs (n) Cytoband lincRNAs (n)
BC-1 10q11.22 1
9p12–p11.2 11
BC-2 6p11.2 1
BC-3 9p24.1 1 3q26.32a 1 4q13.3 1
4p15.1 1 10q11.22 1
7p11.2 1
14q32.33 1
20p11.1 1
10q11.22 1
BC-4 1q44 3
2p25.3 3
3p26.3 6
4q35.2 3 8p23.2 1
5p15.33 1 15q11.1– q11.2 8
8p23.3 1
9p24.2 1
10p15.3 1
11q25 3
12p13.33, 12q24.33 5
13q34 3
15q26.3 1
21q22.3 3
BC-5 11p15.5 1 1q44 1
Xq13.1 4 2p25.3 5
3p26.2,3p26.3 6
4q35.2 7
6q27 6
7q36.3 2
8p23.2 1
10p15.3 1
12q24.33, 12p13.33 1
13q34 3
15q26.3 1
18p11.31,18p11.32 2
BC-6 9p21.3–p21.2 1 9p24.1–p21.3b, 9p24.3–p24.12 27 2p11.1 1
9p12–p11.2, 9p21.3–p21.2 12
10q11.22 3
BC-7 10q11.22 3
aHomozygous Copy Loss.
bLOH.
from 1.2Kb to greater than 18Mb, were predicted among the
seven tumor-normal paired samples (Tables 2 and S2). One hun-
dred and twenty-two lincRNAs were affected by CNV genomic
regions of over 86Mb covering from 0.14% to 100% overlap-
ping aberrations; the majority of events were seen in copy number
losses (Tables S2 and S3).
CNV RESISTANCE OF lincRNA GENES
The overall view for lincRNA gene-associated CNVs and protein-
coding gene harbored CNVs is illustrated in Figure 1A. Unlike
protein-coding genes where CNVs are generally scattered through
each chromosome, lincRNA associated somatic CNVs appear to
demonstrate an uneven distribution throughout the genome in
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the seven tumor-normal pairs. lincRNA associated copy number
losses were preferentially clustered to genomic regions at close
proximity to the telomere of chromosomes whereas few copy
number gains were detected in the central regions.
A further dissection of each CNV-affected region into genic,
lincRNA gene, and intergenic (exclude lincRNA genes) associ-
ated segments showed only 1.8% of the aberrations fell within the
footprint of lincRNAs compared to 37.5% of protein coding genes
and 60.6% of the non-lincRNA intergenic segments (Figure 1D).
Obviously, affected protein coding genes outnumbered lincRNA
associated aberrations over the percentage estimated by chance
(40%). Interestingly, although the intergenic region represents a
higher proportion of CNVs than the genic region, lincRNA region
appears to harbor a lesser proportion of CNVs than the genic
FIGURE 1 | (A) Whole genome view of CNV frequencies for lincRNA
overlapped (Left) and protein coding gene overlapped (right) regions using
an aggregate of seven matched tumor-normal pairs; frequencies were
illustrated using Circos software (Krzywinski et al., 2009) in an outward
direction. Blue in the inner layer represents copy number losses and red in
the middle layer presents copy number gains. Y chromosome was
removed from the outer layer. (B) Comparison of percentages of CNV
affected base pairs in genic, intergenic and lincRNA regions to the total
size of each region, respectively; values from seven paired samples were
averaged. (C) Correlation between percentage of lincRNA overlapped and
genic overlapped CNV to the total size of CNV across seven samples.
(D) Proportion analysis of CNV (non-lincRNA intergenic length = intergenic
length–lincRNA length). All calculations were performed on the basis of a
female genome.
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region. This is reflected by a 2.4-fold higher mean proportion of
CNVs of the genic region compared to that of the lincRNA region
(p > 0.05, Figure 1B). The finding that lincRNA genes may rep-
resent a lesser portion of breast cancer genomic abnormalities
may suggest that they are probably less susceptible to genomic
aberrations than the protein coding genes in breast cancers. In
addition, there is a linear relation (R2 = 0.96) between lincRNA
and genic region (percentage of CNV in length) across 7 samples
(Figure 1C).
INTER-INDIVIDUAL HETEROGENEITY IN lincRNA CNVs
There is tremendous evidence showing that cancer genomes are
complicated and heterogeneous between individuals and even
between tumors within an individual.With complicated nature of
tumors per se, it is not surprising to find the heterogeneity in the
somatic alterations in our samples. Some cancers carried many or
large regions of changes while some exhibited few or none. For
example, Figure 2 depicts data from the primary breast cancer
BC-6 showing substantial allelic losses (downward shifts in the
adjusted logRRs relative to the baseline, Figure 2B) and one copy
number duplication or LOH (BAFs are clustered around values
of 0 and 1 corresponding to genotypes AA and BB, respectively,
Figure 2B) on chromosome 9p23, which affected over 24Mb
base pairs in length and 27 lincRNA (Figure 2C). By contrast,
sample BC-1 most likely remained unchanged except one lin-
cRNA gene harboring allelic imbalances (Table 1). However, a
consensus high frequency of allelic imbalances was observed in
10q11.22 in 4 out of 7 tumors, which affected 4 lincRNAs in this
region.
SELECTIVE lincRNA CNV VALIDATION
To further confirm that our identified lincRNAs are expressed
in breast tissue even though in the context of cancer, since lin-
cRNAs demonstrated high tissue-specific expression signatures,
we queried our lincRNA list against a published expression
database (Cabili et al., 2011) and found that all identified lin-
cRNA genes were reported for expression in breast tissues.
In addition, qPCR was used to selectively validate lincRNA-
associated CNVs showing a predicted recurrence within 7
pairs. Of 33 qPCR reaction assays for 6 lincRNAs, 28 (85%)
were in agreement with the prediction from Nexus (Figure 3).
All six calls for sample BC-4 were detected while five calls
for BC-5 were not detected. Only one recurrent CNV call
(lincRNA-f) was detected by qPCR. Aberrations of the six
lincRNA-associated regions have been reported by other studies
(Table S4).
FIGURE 2 | An example of CNV case analysis revealed large
chromosomal CN loss and LOH at chromosome 9 in patient BC-6.
(A) Whole genome view from chromosome 8–10. (B) An enlarged LogRR
and BAF view of chr9p showed complex aberrations of this region.
(C) Twenty-seven CNV-affected lincRNA genes and tumor suppressor genes
were illustrated across this region.
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FIGURE 3 | Examples of validation of lincRNA CNV using qPCR. Methods
of 2−Ct and standard curve (SC) were compared. Assays from two levels
of gDNA input were averaged and values were presented as the ratio of
normalized tumor against normal sample using alpha-satellite and albumin as
references. Stars represent copy number losses predicted by Nexus and
detected by qPCR. Triangles represent copy number losses predicted by
Nexus, but not detected by qPCR; a cutoff of 0.2 was used for qPCR
(approximately 3 standard deviations of ALB normalized by alpha-satellite).
DISCUSSION
The major objective of this study is to develop a novel
approach specifically applied to the identification of breast
cancer-associated lincRNAs using high density SNP arrays, by
means of which for the first time we report the patterns of
lincRNA CNVs in breast cancer genomes. By comparing the dif-
ferences in genomes between tumors and their matched adjacent
normal host counterparts, the resultant copy number aberrations
represent bona fide biological gene dosages in tumors, which
account for a major portion of cancer genomic structural varia-
tions. Although several studies have reported the landscape of the
cancer genome by examining hundreds of cancer cell lines (Berger
et al., 2011; Curtis et al., 2012; Walker et al., 2012), none of them
specifically investigated genomic aberrations associated with lin-
cRNAs. The new HumanOmni5 Beadchip from Illumina consists
of about 4.3 million SNPs and provides a comprehensive view of
the intergenic portion of the genome, which enables the discov-
ery of small CNVs and defining CNV breakpoints of lincRNAs
with a higher informative rate. Since the critical role of certain
lincRNA(s) in breast cancers as well as in other cancers has been
reported, the development of our approach, implemented in this
platform, has been motivated by the need to address the pres-
ence of lincRNAs harboring CNVs in breast cancers, and likely
contributes to the identification of novel breast cancer-associated
lincRNAs.
The challenges raised in the analysis of SNP array data from
cancers have been extensively discussed, and results derived
from cancer samples may be confounded by numerous factors
including (1) the variable tumor purity (potential contamina-
tion with normal DNA), (2) the non-uniform nature of cancer
genomes including intra-tumor and inter-tumor heterogene-
ity, (3) aneuploidy or polyploidy features between individuals
and chromosomal regions, (4) extensive genomic rearrange-
ments resulting in considerable variations in SNP array data,
and (5) technical artifacts produced by SNP array per se, which
probably requires robust cancer genome specific computational
methods (Peiffer et al., 2006; Heinrichs et al., 2010; Yau et al.,
2010). Theoretically, these problems are magnified in lincRNAs
since their footprints on the genome are less susceptible to
CNVs in comparison with protein-coding regions as inferred
from Figure 1A. However, in our study, primary breast epithe-
lial cultures enriched tumor purity, which minimized the pro-
portion of normal cell and/or stromal contamination. We also
employed the primary cultures at low passage rates (within
less than 3 passages) since additional genomic aberrations can
be acquired during the course of in vitro culture (Stephens
et al., 2009). The overview of lincRNA-associated CNVs across
all samples visually showed a localized preference to chromo-
some ends. This pattern may presumably be attributed to the
likelihood that chromosomal rearrangements in the breast cancer
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genomes may physically initiate from the ends of chromosomes.
This may partially facilitate interchromosomal rearrangements
and intrachromosomal duplications or amplifications, which
have been extensively reported in breast cancers as well as in other
cancers (Stephens et al., 2009). Moreover, some of the tumor
suppressor protein-coding genes present at chromosome ends
have been observed in a high degree of deletions (Cao et al.,
2011).
For a close examination of individual samples, we found dra-
matically localized variations among seven primary cancer cell
clones from either individual samples (Table 2) or aggregations
of all samples (Figure 1) and each harbors its own distinct pat-
tern of genomic CNVs, confirming the heterogeneous nature of
tumors. The LOH present in 9p21.3-24.3 in one of the cases may
indicate that this region carries coding tumor suppressor genes
(e.g., SMARCA2, MTAP, CDKN2A, and CDKN2B, Figure 2C) or
even non-coding suppressor candidates, but is less likely a ran-
dom chromosomal rearrangement event. Future investigations of
this region in a larger dataset could be warranted.
It has been shown that the expression signals of intergenic
transcripts are generally ∼10-fold lower than that of their
protein-coding counterpart mRNAs (Cabili et al., 2011). It is,
therefore, speculated that gene dosages might be an alternative
strategy to compensate for low-expressed lincRNAs, especially in
the context of cancer whose hallmark is complex genetic abnor-
malities. Interestingly, not as we expected, the global pattern of
lincRNAs harboring CNVs revealed much more stable genome
structures for these RNA than those for protein coding or other
intergenic regions, at least in the present breast cancer samples.
Since the genomic regions that remain stable in copy num-
ber may be essential for maintaining cell survival (Park et al.,
2012), lincRNAs could play important roles in cell growth and
metabolism to both normal and tumor cells.
In conclusion, we have described a novel approach for genomic
copy number and LOH profiling for lincRNA genes in breast
cancers using high resolution SNP array. We addressed a number
of problems present in SNP-array–based cancer-associated lin-
cRNA CNV analysis. lincRNA genes apparently manifest a rel-
atively more stable manner than coding genes in terms of sen-
sitivity to gene dosage. We identified a couple of lincRNA gene
candidates in breast cancers with mostly copy number losses.
Further expressional and functional studies on these lincRNAs
would be worthwhile for a better understanding of their roles in
breast cancer development.
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